Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00161720 · ClinicalTrials.gov registry record
Retrospective Study to Capture Dosing and Treatment Outcome Data in Participants With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A clinical trial, sponsored by Baxalta now part of Shire.
- Completed
- Registry status
- 11
- Enrollment target
NCT00161720: Completed study, sponsored by Baxalta now part of Shire.
NCT00161720 is a clinical trial that has completed, run by Baxalta now part of Shire. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00161720 has completed, sponsored by Baxalta now part of Shire.
- COMPLETED
- Registry status
- 11 participants
- Enrollment target
Study Summary
This is a data collection study with the purpose of capturing dosing and treatment outcome data in participants with severe congenital protein C deficiency who were treated with protein C concentrate under an Emergency Use Investigational New Drug Application (IND).
Primary Outcome
Number of participants who received a dose of Protein C in retrospective study will be reported.
Interventions
- DRUG Protein C Concentrate (Human) Vapor Heated
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2005-06-01 |
| Est. Completion | 2005-12-01 |
What the finished NCT00161720 record still lists
NCT00161720 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 11 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Protein C Concentrate (Human) Vapor Heated is the first listed.
NCT00161720 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00161720 about?
NCT00161720 is a clinical study titled "Retrospective Study to Capture Dosing and Treatment Outcome Data in Participants With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND". This is a data collection study with the purpose of capturing dosing and treatment outcome data in participants with severe congenital protein C deficiency who were treated with protein C concentrate under an Emergency Use Investigational New Drug Application (IND).
What is the current status of trial NCT00161720?
This trial is currently completed. The enrollment target is 11 participants. The study started on 2005-06-01. Estimated completion is 2005-12-01.
What interventions are being tested in trial NCT00161720?
The interventions under investigation include: Protein C Concentrate (Human) Vapor Heated (DRUG).
Who is sponsoring clinical trial NCT00161720?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI